Abiraterone for treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 3, 2014, Pages 1313-1320

  Zhou, Zhi Rui ^a   Liu, Shi Xin ^a   Zhang, Tian Song ^b   Xia, Jun ^c   Li, Bo ^d  

^a Tumor Hospital of Jilin Province   (China)

^b LINYI PEOPLE'S HOSPITAL   (China)

^c XIYUAN HOSPITAL   (China)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Abiraterone; Castration resistant; Efficacy; Meta analysis; Prostate cancer; Safety

Indexed keywords

ABIRATERONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 3, HUMAN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD; CASTRATION RESISTANT PROSTATE CANCER; DISEASE COURSE; DISEASE FREE SURVIVAL; HUMAN; MALE; META ANALYSIS; MORTALITY; PATHOLOGY;

ANDROSTENOLS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; KALLIKREINS; MALE; PLACEBOS; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84896836872     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.3.1313     Document Type: Article

References (27)

1. Attard G, Reid AHM, Yap TA, et al (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol, 26, 4563-71.
2. Attard G, Reid AH, A'Hern R, et al (2009). Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol, 27, 3742-8.
3. Balshem H, Helfand M, Schunemann HJ, et al (2011). GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol, 64, 401-6.
4. Beltran H, Beer TM, Carducci MA, et al (2011). New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol, 60, 279-90.
5. Cersosimo RJ (2012). New agents for the management of castration-resistant prostate cancer. Ann Pharmacother, 46, 1518-28.
6. Crawford ED, Eisenberger MA, McLeod DG, et al (1989). A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med, 321, 419-24.
7. Danila DC, Morris MJ, de Bono JS, et al (2010). Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol, 28, 1496-501.
8. de Bono JS, Logothetis CJ, Molina A, et al (2011). Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 364, 1995-2005.
9. Di Lorenzo G, Ferro M, Buonerba C (2012). Sipuleucel-T (Provenge (R)) for castration-resistant prostate cancer. BJU Int, 110, E99-104.
10. Ding H, Yang L, Du W, et al (2013). Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 14, 3337-43.
11. Fizazi K, Scher HI, Molina A, et al (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 13, 983-92.
12. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A (2011). GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol, 64, 380-2.
13. Higgins JPT, Green S (2011). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
14. Kang DI, Chung JI, Ha HK, et al (2013). Korean prostate cancer patients have worse disease characteristics than their American counterparts. Asian Pac J Cancer Prev, 14, 6913-7.
15. Logothetis CJ, Basch E, Molina A, et al (2012). Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol, 13, 1210-7.
16. Moore MA, Ariyaratne Y, Badar F, et al (2010). Cancer epidemiology in South Asia-past, present and future. Asian Pac J Cancer Prev, 11 Suppl 2, 49-66.
17. Nandha R (2012). Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma. J Postgrad Med, 58, 203-6.
18. Ostale S, Ruiz P (2012). Cost-efficacy analysis of licensed drugs for the treatment of metastatic castrate resistant prostate cancer post docetaxel based on hospital drug evaluation methodology in Spain. Value Health, 15, A417.
19. Persson U, Nilsson S, Hjortsberg C, Prutz C (2012). Economic evaluation of abiraterone acetate as treatment for metastatic castration resistant prostate cancer after failure of docetaxel in Sweden. Value Health, 15, A219.
20. Petrylak DP, Tangen CM, Hussain MH, et al (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 351, 1513-20.
21. Reid AHM, Attard G, Danila DC, et al (2010). Significant and sustained antitumor activity in post-docetaxel, castrationresistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol, 28, 1489-95.
22. Ryan CJ, Smith MR, Fong L, et al (2010). Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol, 28, 1481-8.
23. Ryan CJ, Shah S, Efstathiou E, et al (2011). Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res, 17, 4854-61.
24. Ryan CJ, Smith MR, de Bono JS, et al (2012). Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med, 368, 138-48.
25. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
26. Yang LPH (2011). Abiraterone acetate: In metastatic castrationresistant prostate cancer. Drugs, 71, 2067-77.
27. Zhou ZR, Zhu XD, Xia J, et al (2013). Short-term versus longterm hormone therapy plus radiotherapy or prostatectomy for prostate cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol, 139, 783-96.